XAVIER ALDEGUER MANTE

Malalties Digestives i Microbiota
Firma
XAVIER ALDEGUER-MANTE
Posició
Investigador/a Principal

Projectes

Codi oficial: RTC-2017-6467-2 Data inici: 18/09/2018 Data fi: 30/09/2021 Investigador/a principal: XAVIER ALDEGUER MANTE Organisme finançador: MINISTERIO DE ECONOMIA Y COMPETITIVIDAD Ajuda: 182,055 €
Codi oficial: La Marató 201912-31 Data inici: 30/09/2020 Data fi: 30/09/2023 Investigador/a principal: XAVIER ALDEGUER MANTE Organisme finançador: FUNDACIO LA MARATO TV3 Ajuda: 199,812.50 €

Publicacions

Garre-Olmo J, Turró-Garriga O, Martí-Lluch R, Zacarías-Pons L, Alves-Cabratosa L, Serrano-Sarbosa D, Vilalta-Franch J, Ramos R, Girona Healthy Region Study Group

Changes in lifestyle resulting from confinement due to COVID-19 and depressive symptomatology: A cross-sectional a population-based study.

COMPR PSYCHIAT, 2021, 104, 152214-152214 dx.doi.org/10.1016/j.comppsych.2020.152214

Lopez-Siles M, Aldeguer X, Sabat-Mir M, Serra-Pagès M, Duncan SH, Flint HJ, Garcia-Gil LJ, Martinez-Medina M

Evaluation of bacterial biomarkers to aid in challenging inflammatory bowel diseases diagnostics and subtype classification.

World Journal Of Gastrointestinal Pathophysiology, 2020, 11, 64-77 dx.doi.org/10.4291/wjgp.v11.i3.64

Casanova MJ, Chaparro M, Mínguez M, Ricart E, Taxonera C, García-López S, Guardiola J, López-San Román A, Iglesias E, Beltrán B, Sicilia B, Vera MI, Hinojosa J, Riestra S, Domènech E, Calvet X, Pérez-Calle JL, Martín-Arranz MD, Aldeguer X, Rivero M, Monfort D, Barrio J, Esteve M, Márquez L, Lorente R, García-Planella E, de Castro L, Bermejo F, Merino O, Rodríguez-Pérez A, Martínez-Montiel P, Van Domselaar M, Alcaín G, Domínguez-Cajal M, Muñoz C, Gomollón F, Fernández-Salazar L, García-Sepulcre MF, Rodríguez-Lago I, Gutiérrez A, Argüelles-Arias F, Rodriguez C, Rodríguez GE, Bujanda L, Llaó J, Varela P, Ramos L, Huguet JM, Almela P, Romero P, Navarro-Llavat M, Abad Á, Ramírez-de la Piscina P, Lucendo AJ, Sesé E, Madrigal RE, Charro M, García-Herola A, Pajares R, Khorrami S, Gisbert JP

Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients With Inflammatory Bowel Disease: Results From the Eneida Registry.

INFLAMM BOWEL DIS, 2020, 26, 606-616 dx.doi.org/10.1093/ibd/izz192

Marin-Jimenez I, Bastida G, Forés A, Garcia-Planella E, Argüelles-Arias F, Sarasa P, Tagarro I, Fernández-Nistal A, Montoto C, Aguas M, Santos-Fernández J, Bosca-Watts MM, Ferreiro R, Merino O, Aldeguer X, Cortés X, Sicilia B, Mesonero F, Barreiro-de Acosta M

Impact of comorbidities on anti-TNFa response and relapse in patients with inflammatory bowel disease: the VERNE study.

BMJ Open Gastroenterology, 2020, 7, e000351 dx.doi.org/10.1136/bmjgast-2019-000351

Malagón M, Ramió-Pujol S, Serrano M, Amoedo J, Oliver L, Bahí A, Miquel-Cusachs JO, Ramirez M, Queralt-Moles X, Gilabert P, Saló J, Guardiola J, Piñol V, Serra-Pagès M, Castells A, Aldeguer X, Garcia-Gil LJ

New fecal bacterial signature for colorectal cancer screening reduces the fecal immunochemical test false-positive rate in a screening population.

Plos One, 2020, 15, e0243158 dx.doi.org/10.1371/journal.pone.0243158

Malagón M, Ramió-Pujol S, Serrano M, Serra-Pagès M, Amoedo J, Oliver L, Bahí A, Mas-de-Xaxars T, Torrealba L, Gilabert P, Miquel-Cusachs JO, García-Nimo L, Saló J, Guardiola J, Piñol V, Cubiella J, Castells A, Aldeguer X, Garcia-Gil J

Reduction of faecal immunochemical test false-positive results using a signature based on faecal bacterial markers.

ALIMENT PHARM THERAP, 2019, 49, 1410-1420 dx.doi.org/10.1111/apt.15251

Casellas F, Navarro E, Amil P, Barber C, Marín L, Guardiola J, Espín E, Sainz E, Aldeguer X, Gallego M, Murciano F, García-Planella E, Martín-de-Carpi J, Mendive JM, González-Mestre A

Development and validation of the QUECOMIICAT questionnaire: a tool to assess disease-related knowledge in patients with inflammatory bowel disease.

REV ESP ENFERM DIG, 2019, 111, 586-592 dx.doi.org/10.17235/reed.2019.6298/2019

Acero Fernández D, Ferri Iglesias MJ, Buxó Pujolràs M, López Nuñez C, Serra Matamala I, Queralt Molés X, Aldeguer Manté X

Changes in the epidemiology and distribution of the hepatitis C virus genotypes in North-Eastern Spain over the last 35 years.

GASTROENTEROLOGIA Y HEPATOLOGIA, 2018, 41, 2-11 dx.doi.org/10.1016/j.gastrohep.2017.09.004

Monsalve-Hernando C, Crespo L, Ferreiro B, Martín V, Aldeguer X, Opio V, Fernández-Gil PL, Gaspar MJ, Romero E, Lara C, Santander C, Torrealba L, Savescu T, Hermida C

Phase IV noninferiority controlled randomized trial to evaluate the impact on diagnostic thinking and patient management and the test-retest reproducibility of the Gaxilose test for hypolactasia diagnosis.

Medicine, 2018, 97, e13136 dx.doi.org/10.1097/MD.0000000000013136

Chaparro M, Garre A, Ricart E, Iborra M, Mesonero F, Vera I, Riestra S, García-Sánchez V, Luisa De Castro M, Martin-Cardona A, Aldeguer X, Mínguez M, de-Acosta MB, Rivero M, Muñoz F, Andreu M, Bargalló A, González-Muñoza C, Pérez Calle JL, García-Sepulcre MF, Bermejo F, Huguet JM, Cabriada JL, Gutiérrez A, Mañosa M, Villoria A, Carbajo AY, Lorente R, García-López S, Piqueras M, Hinojosa E, Arajol C, Sicilia B, Conesa AM, Sainz E, Almela P, Llaó J, Roncero O, Camo P, Taxonera C, Domselaar MV, Pajares R, Legido J, Madrigal R, Lucendo AJ, Alcaín G, Doménech E, Gisbert JP, GETECCU study group

Short and long-term effectiveness and safety of vedolizumab in inflammatory bowel disease: results from the ENEIDA registry.

ALIMENT PHARM THERAP, 2018, 48, 839-851 dx.doi.org/10.1111/apt.14930

Propietat intel·lectual

Xavier Aldeguer Mante

METHOD FOR DIAGNOSING COLORECTAL CANCER FROM A HUMAN FECES SAMPLE BY QUANTITIVE PCR, PRIMERS AND KIT

Número de publicació: WO2015132273 Data de publicació: 2015-09-11

Xavier Aldeguer Mante

METHOD FOR THE QUANTIFICATION OF FAECALIBACTERIUM PRAUSNITZII PHYLOGROUP I AND/OR PHYLOGROUP II MEMBERS AND THE USE THEREOF AS BIOMARKERS

Número de publicació: WO2017025617 Data de publicació: 2017-02-16

Formulari de contacte

menu